Note about the press release published on April 1st

Solvay confirms it is proceeding with an analysis of various options for its pharmaceutical activities

Contacts

Media Relations
Erik De Leye
+32 2 264 1530
Investor Relations
Patrick Verelst
+32 2 264 1540